Please login to the form below

Not currently logged in
Email:
Password:

Bristol-Myers Squibb names new CEO

Lamberto Andreotti will take over from James Cornelius as CEO at Bristol-Myers Squibb, with Cornelius staying on as chairman  

Bristol-Myers Squibb (BMS) has announced that Lamberto Andreotti, 59, will become the company's chief executive officer on May 4, when James M Cornelius, 66, current chairman and CEO, retires. At the request of the board, Cornelius will remain as chairman. 

"Jim successfully led our transformation into a next-generation biopharma leader with his strategic leadership and consistent focus on delivering our commitments. I am personally grateful for this opportunity to lead Bristol-Myers Squibb in the next phase of our biopharma journey," said Lamberto Andreotti, who is currently president, chief operating officer and a member of the board.  

Lamberto has the full support of Cornelius, who said: "Lamberto has demonstrated extraordinary leadership as president and chief operating officer and I believe he is the natural candidate to replace me as CEO. I have a high level of confidence in Lamberto and that is shared by everyone who has seen him consistently and successfully drive performance."  

Andreotti has been president and chief operating officer since March 2009, responsible for the global pharmaceutical business. He has been with BMS for 12 years in senior international roles. Prior to this he held senior roles at KABI Pharmacia and Pharmacia & Upjohn. 

3rd March 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M&F Health

M&F Health is a full service communications agency, dedicated to the health and wellbeing sector. We are an independent amongst...

Latest intelligence

Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...

Infographics